Skip to content

AxoGen

US · AXGN #2714 by market cap Listed 1970
55.75 -0.60 -1.06%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 55.79 -0.99%
After-hours 56.10 +0.63%
Overnight 56.28 -0.12%
58.6334.6255.752026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on AXGN?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +68.6% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 11.7% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → B

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall B

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth B

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 17.6% Better than 79%
Net income CAGR (3Y) -41.5% Better than 6%
Free cash flow CAGR (3Y) 31.0% Better than 75%
Profitability C

How much profit the business keeps from each dollar of sales and capital.

Gross margin 74.3% Better than 86%
Operating margin -3.5% Better than 18%
Net margin -7.0% Better than 18%
Return on equity -13.5% Better than 18%
Return on invested capital -4.3% Better than 23%
Momentum A+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 10.6% Better than 90%
6-month return 36.3% Better than 92%
12-month return (ex latest month) 36.5% Better than 75%
Distance below 52-week high 6.6% Better than 91%
Financial Health C+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.1x Better than 87%
Debt to assets 30.5% Better than 41%
Interest coverage -1.0x Better than 22%
Free cash flow / net income 102.6% Better than 40%
Analyst View C+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 4.4% Better than 8%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -0.32%
1M +54.13%
3M +20.05%
6M +30.59%
YTD +70.33%
1Y +117.18%
3Y +821.49%
5Y +471.21%

Key statistics

Price & volume

Prev close
56.35
Open
55.71
Day range
55.03 - 56.91
Avg price
55.76
Volume
876.07K
Turnover
48.85M
Amplitude
3.34%
52-week range
26.92 - 59.72

Valuation

P/E
-163.97
P/E (TTM)
-88.49
P/B
6.71
EPS
-0.34
Net profit
-20.31M
Net assets
496.12M

Share structure

Market cap
3.33B
Float cap
3.04B
Shares out
59.73M
Float shares
54.61M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 88% of range
26.92 59.72

6.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-9.46M net over the window

Short interest

Shares short
6.99M
As of
2026-10-30

Frequently asked questions

What is the current stock price of AxoGen (AXGN)?

AxoGen last traded at 55.75. This page shows a periodic quote snapshot. Check the displayed quote time.

What is AxoGen's market cap?

About 3.33B.

What is the P/E ratio of AxoGen?

The trailing twelve-month P/E is -88.49. The Valuation tab shows it against the stock's own five-year range.

Does AxoGen pay a dividend?

AxoGen does not currently pay a regular dividend.

Is AxoGen a buy according to analysts?

The consensus of 11 analysts is a Buy rating, with an average 12-month price target of 58.18, which implies 4.4% upside from the current price. This is not investment advice.

What is AxoGen's StockVane Quant Rating?

The StockVane Momentum strategy currently rates AxoGen a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

AxoGen discussion 0 comments

Add a comment